Aditxt, Inc. has completed the acquisition of Ignite Proteomics, enhancing its oncology initiatives. The deal involves 36,000 shares of Series A-2 Convertible Preferred Stock valued at $36 million, aimed at optimizing cancer therapy selection.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.